As of 2026-08-17, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -9.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 788.07 mil USD. Aclaris's TTM EBITDA according to its financial statements is -82.04 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 12.8x | 8.7x |
| Forward P/E multiples | 11.8x - 15.0x | 13.8x |
| Fair Price | (6.79) - (7.39) | (6.46) |
| Upside | -217.6% - -227.9% | -211.7% |
| Date | EV/EBITDA |
| 2026-08-17 | -9.72 |
| 2026-08-14 | -9.61 |
| 2026-08-13 | -9.74 |
| 2026-08-12 | -9.71 |
| 2026-08-11 | -9.84 |
| 2026-08-10 | -9.81 |
| 2026-08-07 | -9.83 |
| 2026-08-06 | -10.13 |
| 2026-08-05 | -10.59 |
| 2026-08-04 | -9.95 |
| 2026-08-03 | -9.18 |
| 2026-07-31 | -8.62 |
| 2026-07-30 | -8.82 |
| 2026-07-29 | -8.48 |
| 2026-07-28 | -8.84 |
| 2026-07-27 | -8.91 |
| 2026-07-24 | -8.67 |
| 2026-07-23 | -9.09 |
| 2026-07-22 | -9.33 |
| 2026-07-21 | -9.45 |
| 2026-07-20 | -9.25 |
| 2026-07-17 | -9.44 |
| 2026-07-16 | -8.89 |
| 2026-07-15 | -9.30 |
| 2026-07-14 | -9.01 |
| 2026-07-13 | -9.13 |
| 2026-07-10 | -9.26 |
| 2026-07-09 | -9.49 |
| 2026-07-08 | -9.15 |
| 2026-07-07 | -9.33 |
| 2026-07-06 | -9.11 |
| 2026-07-02 | -9.23 |
| 2026-07-01 | -8.86 |
| 2026-06-30 | -8.77 |
| 2026-06-29 | -8.31 |
| 2026-06-26 | -8.28 |
| 2026-06-25 | -8.12 |
| 2026-06-24 | -7.92 |
| 2026-06-23 | -8.14 |
| 2026-06-22 | -8.01 |
| 2026-06-18 | -7.43 |
| 2026-06-17 | -7.29 |
| 2026-06-16 | -7.15 |
| 2026-06-15 | -7.19 |
| 2026-06-12 | -7.12 |
| 2026-06-11 | -7.21 |
| 2026-06-10 | -6.75 |
| 2026-06-09 | -7.09 |
| 2026-06-08 | -7.19 |
| 2026-06-05 | -7.19 |